JonesTrading analyst Soumit Roy reiterated a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of $30.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Soumit Roy’s rating is based on the promising developments in Precision BioSciences’ gene editing programs, particularly the PBGENE-HBV and PBGENE-DMD assets. The company has started releasing clinical data for PBGENE-HBV, showing potential in treating chronic Hepatitis B, with significant reductions in Hepatitis B surface antigen observed in early trials. Additionally, the PBGENE-DMD program is positioned as a potential business development opportunity, with the possibility of entering clinical trials independently by the first half of 2026.
Furthermore, the financial projections for PBGENE-HBV indicate a substantial market opportunity, with estimated peak sales of $600 million worldwide by 2040. This is based on a conservative market penetration estimate and the prevalence of chronic Hepatitis B in the U.S. The absence of significant adverse events in initial trials also supports the positive outlook. These factors collectively contribute to the Buy rating, with a price target of $30.
In another report released on March 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.